Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00224042
Status:
COMPLETED
Last Update Posted:
2012-03-29
First Post:
2005-09-13
Brief Title:
Effect of Ferrlecit Versus Oral Iron on Iron Deficient Chronic Kidney Disease CKD Patients Receiving Erythropoietic Agents
Sponsor:
Watson Pharmaceuticals
Organization:
Watson Pharmaceuticals
Study Overview
Official Title:
A Randomized Controlled Open-label Study of the Safety and Efficacy of Ferrlecit vs Oral Iron in Iron Deficient Patients With Chronic Kidney Disease Being Treated With Erythropoietic Therapy
Status:
COMPLETED
Status Verified Date:
2012-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study compares the effect of Ferrlecit a form of intravenous iron to ferrous sulfate a form of oral iron in treating anemia and iron deficiency in chronic kidney disease patients who are receiving erythropoietic agents such as Procrit and Aranesp
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None